BioPharma Dive20h
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Fierce Pharma23h
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Novartis8d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...
pharmaphorum2d
Novartis and GSK’s multi-billion dollar swaps to transform both companies
The deal includes two recently approved GSK products for metastatic melanoma ... Looking ahead, this positions Novartis well for future healthcare industry dynamics." For GSK, the divestment ...
Pharma company to lay off 427 at its N.J. headquarters
Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...
2NVS : FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...
Reuters23d
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
Traditionally, pharmaceutical products have always been exempt from ... 12 years as chairman at the company's AGM on Friday, said Novartis assumed the financial impact of the tariffs would be ...
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
ZURICH (Reuters) -Novartis is not panicking about higher ... what actually happens is another. Traditionally, pharmaceutical ...
Morningstar16d
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence ...